Cargando…

ALTERED PLASMA CYTOKINE CONCENTRATIONS ARE ASSOCIATED WITH THE CLINICAL SEVERITY OF PATIENTS WITH COVID-19

INTRODUCTION: The novel Coronavirus (SARS-CoV-2), responsible for severe acute respiratory syndrome, has emerged as a threat to humans since December 2019, and the search for a better understanding of the pathophysiology of coronavirus disease 2019 (COVID-19) and its definitive treatment is still in...

Descripción completa

Detalles Bibliográficos
Autores principales: Alagbe, AE, Pedroso, GA, Justo-Junior, AS, Costa, E, Oliveira, BB, Maia, GAF, Albuquerque, DM, Módena, JLP, Costa, FF, Santos, MNND
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Editora Ltda. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576008/
http://dx.doi.org/10.1016/j.htct.2022.09.1130
_version_ 1784811436247089152
author Alagbe, AE
Pedroso, GA
Justo-Junior, AS
Costa, E
Oliveira, BB
Maia, GAF
Albuquerque, DM
Módena, JLP
Costa, FF
Santos, MNND
author_facet Alagbe, AE
Pedroso, GA
Justo-Junior, AS
Costa, E
Oliveira, BB
Maia, GAF
Albuquerque, DM
Módena, JLP
Costa, FF
Santos, MNND
author_sort Alagbe, AE
collection PubMed
description INTRODUCTION: The novel Coronavirus (SARS-CoV-2), responsible for severe acute respiratory syndrome, has emerged as a threat to humans since December 2019, and the search for a better understanding of the pathophysiology of coronavirus disease 2019 (COVID-19) and its definitive treatment is still in progress. OBJECTIVE: To evaluate the plasma pro- and anti-inflammatory cytokines in COVID-19 patients and their associations with the disease severity and outcome. METHODS: Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)-confirmed COVID-19 unvaccinated patients at the Hospital de Clínicas (HC), UNICAMP, Campinas, SP, were enrolled. Clinical and laboratory data were extracted from the medical records, and the plasma cytokines levels were quantified using LUMINEX and ELISA. RESULTS: There were 154 COVID-19 patients (99 survivors and 55 non-survivors) with male:female of 1.4:1, and a median age of 60 years. The non-survivors were older than survivors (65 vs. 55 years, p < 0.0001); and coronary artery disease and autoimmunity, disease severity, and oxygen therapy, intensive care, and intubation were associated with mortality. Non-survivors had higher leukocyte and neutrophil counts, and RDW and lower lymphocyte count at diagnosis. Non-survivors had higher levels of pro-inflammatory (TNF-α, IL-6, IFN-γ, CCL3, IL-17/IL-17A, IL-8, G-CSF, CCL2/MCP-1) and anti-inflammatory (IL-1ra and IL-27) cytokines, but lower TGF-β levels than the survivors. TNF-α levels were positively correlated with all studied cytokines except TGF-β, while TGF-β levels were negatively correlated with TNF-α, IL-6, CCL3, G-CSF, and IL-27. IL-27 levels were significantly correlated with all the cytokines except IL-37 and IL-17E. More than half (55.2%) of our patients had severe COVID-19, 18.8% had moderate, 16.2% had critical, 5.2% had mild, and 4.5% were asymptomatic. Majority of the patients (68.2%) required ICU care and had higher TNF-α, IL-6, IL-8, IL-17, CCL3, CCL2, IL-1ra, and IL-27 than others. 59.7% of the patients required endotracheal intubation and had higher TNF-α, IL-6, IL-8, CCL3, CCL2, and IL-1ra than those who did not have intubation. TNF-α, IL-6, and IL-8 had the highest Area Under the Receiver Operating Characteristics (AUROC) curve, sensitivity, and specificity for predicting mortality in these COVID-19 patients. DISCUSSION AND CONCLUSION: The altered levels of pro- and anti-inflammatory cytokines support the role of SARS-CoV-2 in inducing cytokine storm, and higher concentrations seen in the deceased patients meant a more severe storm. Also, the increased leukocytes and neutrophils in our patients could have led to the release of reactive oxygen species, and end-organ damage, thus leading to poor outcomes. This study showed that the levels of these cytokines could be used as markers of mortality in COVID-19. It is possible to suggest that TNF, IL-6, and IL-8 levels at diagnosis could be efficient predictors of fatal outcomes in COVID-19 patients. If properly measured at diagnosis, these markers could be useful for triaging and predicting the outcome of COVID-19, thus guiding the treatment of the COVID-19. FUNDING: CNPq (#190374/2017-9), CAPES, FAPESP and FAEPEX (#338619).
format Online
Article
Text
id pubmed-9576008
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Editora Ltda.
record_format MEDLINE/PubMed
spelling pubmed-95760082022-10-17 ALTERED PLASMA CYTOKINE CONCENTRATIONS ARE ASSOCIATED WITH THE CLINICAL SEVERITY OF PATIENTS WITH COVID-19 Alagbe, AE Pedroso, GA Justo-Junior, AS Costa, E Oliveira, BB Maia, GAF Albuquerque, DM Módena, JLP Costa, FF Santos, MNND Hematol Transfus Cell Ther Article INTRODUCTION: The novel Coronavirus (SARS-CoV-2), responsible for severe acute respiratory syndrome, has emerged as a threat to humans since December 2019, and the search for a better understanding of the pathophysiology of coronavirus disease 2019 (COVID-19) and its definitive treatment is still in progress. OBJECTIVE: To evaluate the plasma pro- and anti-inflammatory cytokines in COVID-19 patients and their associations with the disease severity and outcome. METHODS: Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR)-confirmed COVID-19 unvaccinated patients at the Hospital de Clínicas (HC), UNICAMP, Campinas, SP, were enrolled. Clinical and laboratory data were extracted from the medical records, and the plasma cytokines levels were quantified using LUMINEX and ELISA. RESULTS: There were 154 COVID-19 patients (99 survivors and 55 non-survivors) with male:female of 1.4:1, and a median age of 60 years. The non-survivors were older than survivors (65 vs. 55 years, p < 0.0001); and coronary artery disease and autoimmunity, disease severity, and oxygen therapy, intensive care, and intubation were associated with mortality. Non-survivors had higher leukocyte and neutrophil counts, and RDW and lower lymphocyte count at diagnosis. Non-survivors had higher levels of pro-inflammatory (TNF-α, IL-6, IFN-γ, CCL3, IL-17/IL-17A, IL-8, G-CSF, CCL2/MCP-1) and anti-inflammatory (IL-1ra and IL-27) cytokines, but lower TGF-β levels than the survivors. TNF-α levels were positively correlated with all studied cytokines except TGF-β, while TGF-β levels were negatively correlated with TNF-α, IL-6, CCL3, G-CSF, and IL-27. IL-27 levels were significantly correlated with all the cytokines except IL-37 and IL-17E. More than half (55.2%) of our patients had severe COVID-19, 18.8% had moderate, 16.2% had critical, 5.2% had mild, and 4.5% were asymptomatic. Majority of the patients (68.2%) required ICU care and had higher TNF-α, IL-6, IL-8, IL-17, CCL3, CCL2, IL-1ra, and IL-27 than others. 59.7% of the patients required endotracheal intubation and had higher TNF-α, IL-6, IL-8, CCL3, CCL2, and IL-1ra than those who did not have intubation. TNF-α, IL-6, and IL-8 had the highest Area Under the Receiver Operating Characteristics (AUROC) curve, sensitivity, and specificity for predicting mortality in these COVID-19 patients. DISCUSSION AND CONCLUSION: The altered levels of pro- and anti-inflammatory cytokines support the role of SARS-CoV-2 in inducing cytokine storm, and higher concentrations seen in the deceased patients meant a more severe storm. Also, the increased leukocytes and neutrophils in our patients could have led to the release of reactive oxygen species, and end-organ damage, thus leading to poor outcomes. This study showed that the levels of these cytokines could be used as markers of mortality in COVID-19. It is possible to suggest that TNF, IL-6, and IL-8 levels at diagnosis could be efficient predictors of fatal outcomes in COVID-19 patients. If properly measured at diagnosis, these markers could be useful for triaging and predicting the outcome of COVID-19, thus guiding the treatment of the COVID-19. FUNDING: CNPq (#190374/2017-9), CAPES, FAPESP and FAEPEX (#338619). Published by Elsevier Editora Ltda. 2022-10 2022-10-15 /pmc/articles/PMC9576008/ http://dx.doi.org/10.1016/j.htct.2022.09.1130 Text en Copyright © 2022 Published by Elsevier Editora Ltda. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Alagbe, AE
Pedroso, GA
Justo-Junior, AS
Costa, E
Oliveira, BB
Maia, GAF
Albuquerque, DM
Módena, JLP
Costa, FF
Santos, MNND
ALTERED PLASMA CYTOKINE CONCENTRATIONS ARE ASSOCIATED WITH THE CLINICAL SEVERITY OF PATIENTS WITH COVID-19
title ALTERED PLASMA CYTOKINE CONCENTRATIONS ARE ASSOCIATED WITH THE CLINICAL SEVERITY OF PATIENTS WITH COVID-19
title_full ALTERED PLASMA CYTOKINE CONCENTRATIONS ARE ASSOCIATED WITH THE CLINICAL SEVERITY OF PATIENTS WITH COVID-19
title_fullStr ALTERED PLASMA CYTOKINE CONCENTRATIONS ARE ASSOCIATED WITH THE CLINICAL SEVERITY OF PATIENTS WITH COVID-19
title_full_unstemmed ALTERED PLASMA CYTOKINE CONCENTRATIONS ARE ASSOCIATED WITH THE CLINICAL SEVERITY OF PATIENTS WITH COVID-19
title_short ALTERED PLASMA CYTOKINE CONCENTRATIONS ARE ASSOCIATED WITH THE CLINICAL SEVERITY OF PATIENTS WITH COVID-19
title_sort altered plasma cytokine concentrations are associated with the clinical severity of patients with covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576008/
http://dx.doi.org/10.1016/j.htct.2022.09.1130
work_keys_str_mv AT alagbeae alteredplasmacytokineconcentrationsareassociatedwiththeclinicalseverityofpatientswithcovid19
AT pedrosoga alteredplasmacytokineconcentrationsareassociatedwiththeclinicalseverityofpatientswithcovid19
AT justojunioras alteredplasmacytokineconcentrationsareassociatedwiththeclinicalseverityofpatientswithcovid19
AT costae alteredplasmacytokineconcentrationsareassociatedwiththeclinicalseverityofpatientswithcovid19
AT oliveirabb alteredplasmacytokineconcentrationsareassociatedwiththeclinicalseverityofpatientswithcovid19
AT maiagaf alteredplasmacytokineconcentrationsareassociatedwiththeclinicalseverityofpatientswithcovid19
AT albuquerquedm alteredplasmacytokineconcentrationsareassociatedwiththeclinicalseverityofpatientswithcovid19
AT modenajlp alteredplasmacytokineconcentrationsareassociatedwiththeclinicalseverityofpatientswithcovid19
AT costaff alteredplasmacytokineconcentrationsareassociatedwiththeclinicalseverityofpatientswithcovid19
AT santosmnnd alteredplasmacytokineconcentrationsareassociatedwiththeclinicalseverityofpatientswithcovid19